Nalaganje...
Emerging treatment options for patients with high-risk myelodysplastic syndrome
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell morphology, and a variable risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and d...
Shranjeno v:
| izdano v: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7675905/ https://ncbi.nlm.nih.gov/pubmed/33240476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720955006 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|